This randomized controlled trial investigates the neurophysiological, physiological, and attentional effects of Cognitive-Behavioral Therapy (CBT) in individuals with restrictive-type anorexia nervosa (AN). The study compares two groups: one receiving a 12-week CBT intervention, and one placed on a waitlist (no active treatment during the study period). All participants undergo pre- and post-intervention assessments using electroencephalography (EEG), galvanic skin response (GSR), and eye-tracking while exposed to visual stimuli related to food, body image, and self-appearance. The primary outcomes include neural changes in attention and emotional processing (P300, LPP, frontal alpha asymmetry), physiological arousal (skin conductance), and visual attention biases (fixation duration and gaze distribution). The aim is to determine whether CBT leads to measurable improvements in neurobiological and attentional mechanisms related to body image disturbance and food-related anxiety in AN, contributing to biomarker-informed psychotherapy approaches.

Anorexia nervosa (AN) is a severe psychiatric disorder characterized by distorted body image, food restriction, and intense fear of weight gain. Despite the effectiveness of Cognitive-Behavioral Therapy (CBT) in targeting maladaptive cognitions and behaviors, its underlying neurophysiological mechanisms remain insufficiently understood. This study aims to evaluate the effects of a 12-week CBT intervention on neural, physiological, and attentional responses in individuals with restrictive-type AN using a randomized controlled trial design.

Sixty female participants (aged 18-35) with restrictive-type AN will be recruited and randomly assigned to one of two groups: a CBT intervention group (n = 30) and a waitlist control group (n = 30). Both groups will undergo baseline and post-intervention assessments using EEG, GSR, and eye-tracking. The CBT intervention will consist of weekly 60-minute sessions for 12 weeks, delivered by trained therapists, and will target body image distortion, cognitive restructuring, exposure to food-related stimuli, emotional regulation, and avoidance behaviors.

During the experimental task, participants will view a series of visual stimuli including (1) self-images (unaltered, altered-thin, altered-overweight), (2) food images (low- vs. high-calorie), and (3) images of other female bodies (thin vs. normal weight). EEG markers of interest include P300 (attentional salience), Late Positive Potential (LPP; sustained emotional reactivity), and frontal alpha asymmetry (indicative of affect regulation and self-referential processing). It is hypothesized that CBT will lead to reductions in P300 and LPP amplitudes and an increase in left-frontal cortical activity, indicating enhanced emotional control and reduced fixation on thin-ideal stimuli.

GSR will be used to assess physiological arousal in response to distressing stimuli. It is expected that post-CBT participants will exhibit lower skin conductance responses (SCRs) to body and food images, indicating improved autonomic regulation. Eye-tracking data will capture fixation durations and gaze patterns. Participants in the CBT group are expected to show less visual attention toward "problematic" body areas (waist, stomach, thighs) and reduced avoidance of high-calorie food images compared to the waitlist group.

Participants will also complete standardized psychometric instruments including the Eating Disorder Examination Questionnaire (EDE-Q), Beck Depression Inventory-II (BDI-II), Beck Anxiety Inventory (BAI), the Yale-Brown Obsessive-Compulsive Scale for Body Dysmorphic Disorder (YBOCS-BDD), and the Cognitive Emotion Regulation Questionnaire (CERQ) at both time points.

This trial will provide critical insights into the neurophysiological and attentional mechanisms of CBT in AN, aiming to identify objective biomarkers of therapeutic change. Results may inform precision-based treatment models and support the development of digitally enhanced or neuromodulation-augmented therapies for eating disorders.

Inclusion Criteria:

• Female participants aged 18 to 35
• Meeting DSM-5 diagnostic criteria for restrictive-type anorexia nervosa
• Body Mass Index (BMI) between 15.0 and 18.5
• Medically stable to participate in psychological and neurophysiological assessments
• Willingness to participate in weekly therapy sessions (for the CBT group) and to complete pre- and post-assessments
• Ability to provide informed consent

Exclusion Criteria:

• Current or past diagnosis of bulimia nervosa, binge-eating disorder, or other eating disorders
• Presence of comorbid severe psychiatric disorders (e.g., psychosis, bipolar disorder, substance use disorder)
• History of neurological illness or traumatic brain injury
• Use of psychotropic medication within the last 6 weeks
• Prior participation in structured Cognitive-Behavioral Therapy for an eating disorder
• Pregnancy
• Visual or neurological impairments that would prevent accurate EEG, GSR, or eye-tracking recordings

De-identified individual participant data (IPD) for all primary and secondary outcome measures (EEG, GSR, eye-tracking, and psychometric scores) will be shared upon reasonable request. Data will be shared in compliance with institutional ethics and data protection regulations.

IPD and supporting materials will be available beginning 6 months after publication of the primary results and will remain available for up to 5 years upon request.

Qualified researchers affiliated with academic institutions may request access to the IPD and supporting materials for ethically approved secondary analyses. Requests must include a brief research proposal and will be reviewed by the study investigators. Data will be shared via secure institutional transfer platforms upon data use agreement. Qualified researchers affiliated with academic institutions may request access to the IPD and supporting materials for ethically approved secondary analyses. Requests must include a brief research proposal and will be reviewed by the study investigators. Data will be shared via secure institutional transfer platforms upon data use agreement.